Vials on the Wegovy line at the Novo Nordisk A/S manufacturing centers in Hillerod, Denmark, on Friday, March 8, 2024. Â
Bloomberg|Bloomberg|Getty Images
LONDON â $” Shares of Denmark’s Zealand Pharma stood out virtually 23% in Friday early morning bargains, scratching a document high after an early-stage research of its weight-loss medicine opposition generated favorable outcomes.
The firm stated Thursday that a program of 16 once a week high dosages of long-acting amylin analog petrelintide decreased body weight by as much as 8.6% usually in the research. A sugar pill medicine brought about a body weight decline of 1.7%.
One out of 48 research individuals took out because of unfavorable results.
Petrelintide was “evaluated to be risk-free and well endured whatsoever dosage degrees” and the outcomes offered “durable assistance” for its prospective as a choice to GLP-1 receptor agonist-based treatments for weight monitoring, Zealand Pharma stated in a release.
GLP-1RA-based therapies consist of Ozempic, the diabetic issues medicine generated by fellow Danish pharmaceutical company Novo Nordisk, which has actually taken off in appeal internationally for its weight-loss results. Rising need for Ozempic and excessive weight medicine Wegovy have actually pushed Novo Nordisk to end up being Europe’s a lot of beneficial firm.
The last couple of years have actually seen an ever-intensifying race to create competing therapies, attracting loads of oppositions to market leaders Novo Nordisk and the United State’ Eli Lilly.
David Kendall, primary clinical police officer of Zealand Pharma, stated that the petrelintide research sustains the firm’s sentence that the medicine “is quite possibly endured and can possibly play a crucial duty as a choice to incretin-based treatments for the monitoring of obese and excessive weight.”
It might “supply weight-loss equivalent to GLP-1 receptor agonists with a much better client experience,” Kendall included.
The firm currently prepares to check petrelintide in a Stage 2 mid-stage scientific test.
Experts at Jefferies stated in a Thursday note that the preliminary outcomes suggest that the medicine “ticks all packages.” They sustain a “feasible duty for amylin as a much more bearable choice to GLP-1s,” with the capacity for weight-loss “at the very least comparable.”
Zealand Pharma is independently examining the prospective weight-loss medicine medicine survodutide in a collaboration with Germany’s Boehringer Ingelheim. Postive Stage 2 test results for that medicine in February increased Zealand’s share cost at the time.
Zealand Pharma share cost.
